Ex vivo expansion of TIL with the IL-2-based systems greatly reduces CD27 and CD28 expression, resulting in reduced persistence and subsequent limited anti-tumor activity in vivo[24-27,39]. The gene discussed is IL2; the disease is neoplasm.